FORM 4

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations may
continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Repo GOLDBERG DAVID C		2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 			
C/O ENZO BIOCHEM	^{virst)} NC, 527 MA		3. Date of Earliest Transaction (Month/Day/Year) 04/20/2004						X_ Officer (give title below) Other (specify below) VP of Business Development		
(4. If Amendment, Date Original Filed(Month/Day/Year) 04/22/2004					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
NEW YORK, NY 10022											
(City)	State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	1	7. Nature of Indirect Beneficial
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts calls warrants options convertible securities)

(e.g., puts, cans, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Num	ber	6. Date Exercisab	le and Expiration	7. Title and	Amount	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	tion	of	Date		of Underlying D		Derivative	Derivative	Ownership	of Indirect	
Security	or Exercise	(Month/Day/Year)	any	Code		Derivat	ivative (Month/Day/Year)		Securities Security		Security	Securities	Form of	Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Securiti	curities		(Instr. 3 and 4) (Instr. 5)		(Instr. 5)	Beneficially	Derivative	Ownership	
	Derivative					Acquire	iired					Owned	Security:	(Instr. 4)	
	Security					(A) or							Following	Direct (D)	
						Dispose	ed						Reported	or Indirect	
						of (D)							Transaction(s)	< / </td <td></td>	
						(Instr. 3	3, 4,	,					(Instr. 4)	(Instr. 4)	
						and 5)									
											Amount				
								Dete			or				
								Date Exercisable	Expiration Date	Title	Number				
								Exercisable	•		of				
				Code	V	(A)	(D)				Shares				
Incentive															
	\$ 7.37	04/20/2004		М		6,700		05/05/1994 <mark>(1)</mark>	05/04/2004(1)	Common	6,700	\$ 0	73,628 (2)	D	
Stock	\$ 7.57	04/20/2004		IVI		0,700		03/03/1994	03/04/2004	Stock	0,700	\$0	/3,028	D	
Option															

Reporting Owners

	Relationships									
Reporting Owner Name / Address	Director	10% Owner	Officer	Other						
GOLDBERG DAVID C C/O ENZO BIOCHEM INC 527 MADISON AVE NEW YORK, NY 10022			VP of Business Development							

Signatures

/s/ David C. Goldberg	04/22/2004
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vested as to 25% of the shares on the one (1) year anniversary of the date of grant (5/5/94) and 25% on each one year anniversary thereafter.
- As of the date hereof, the Reporting Person directly beneficially owns 15,209 shares of Common Stock, 2,164 shares of Common Stock in Enzo Biochem's 401K plan and 55,322 options to (2) purchase Common Stock, par value \$.01 per share which are currently exercisable. The Reporting Person also has an indirect beneficial interest in 933 shares as custodian for certain of his children.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.